Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Qual Life Res ; 23(3): 869-75, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24052325

RESUMO

PURPOSE: Family Dermatology Life Quality Index (FDLQI) is an instrument for assessing the quality of life of family members of dermatologic patients. The aim of this study was to describe the cultural adaptation of this questionnaire and to assess psychometric properties of the Persian version. METHODS: At first, the questionnaire was translated into Persian, and then back-translation was performed. The whole cycle was repeated until a consensus was reached about the optimal translation. In the next step, cognitive debriefing was performed, and after approval of the Persian version by FDLQI developers, it was distributed among 100 family members of dermatological patients in order to evaluate its validity and reliability. RESULTS: Mean age of participants was 37.1 years (±12.3). Mean score of FDLQI was 15.4 (±5.5) with maximum and minimum scores of 30 and 6, respectively. The quality of life of studied participants showed no significant difference based on age-group, sex, educational level and the family relationship. Cronbach's alpha was calculated as 0.87. Exploratory factor analysis revealed a one-factor solution that accounted for 40.7 % of the variance. The unidimensional model was supported by confirmatory factor analysis. CONCLUSIONS: The results of the present study showed that the Persian version of FDLQI has acceptable factorial validity and internal consistency reliability.


Assuntos
Relações Familiares , Psicometria/normas , Qualidade de Vida , Dermatopatias/psicologia , Inquéritos e Questionários/normas , Adulto , Efeitos Psicossociais da Doença , Análise Fatorial , Feminino , Humanos , Relações Interpessoais , Entrevista Psicológica , Irã (Geográfico) , Masculino , Pessoa de Meia-Idade , Pesquisa Qualitativa , Reprodutibilidade dos Testes , Perfil de Impacto da Doença , Dermatopatias/economia , Fatores Socioeconômicos , Tradução , Traduções , Adulto Jovem
2.
J Eur Acad Dermatol Venereol ; 25(5): 587-91, 2011 May.
Artigo em Inglês | MEDLINE | ID: mdl-20666876

RESUMO

BACKGROUND: Cutaneous leishmaniasis (CL) is endemic in developing countries. Several types of treatments have been suggested, but none of them is completely effective and without side-effects. CO(2) laser has a specific thermolysis effect on infected tissues in CL. OBJECTIVES: To determine the efficacy and safety of CO(2) laser vs. combined cryotherapy and intralesional meglumine antimoniate (glucantime) in dry-type CL. METHODS: This is a prospective, randomized open trial study (Kerman, Iran) from November 2007 to August 2009. A total of 96 patients were randomly assigned to receive one session of CO(2) laser therapy and 95 patients on combined cryotherapy biweekly with intralesional meglumine antimoniate weekly until complete cure or up to 12 weeks, whichever is earlier. Clinical and laboratory cure, defined as complete re-epithelialization of 100%, complete flattening of induration and negative smear of lesions compared with baseline at weeks 2, 6, 12 and 16, and also at the time of complete cure (week 2, 6, 12 or 16). RESULTS: Of 191 participants, 80 patients with 95 lesions in group A and 80 patients with 95 lesions in group B completed the study. Complete cure was 93.7% (89/95 lesions) in group A and 78% (74/95 lesions) in group B. Complications were similar in the two groups and were limited to the ulcer sites. CONCLUSIONS: The CO(2) laser was more effective in treating dry-type cutaneous leishmaniasis than combined cryotherapy and intralesional glucantime and resulted in a shorter healing time (6 weeks vs. 12 weeks) with a single treatment session.


Assuntos
Antiprotozoários/uso terapêutico , Crioterapia/métodos , Terapia a Laser/métodos , Lasers de Gás/uso terapêutico , Leishmaniose Cutânea/terapia , Meglumina/uso terapêutico , Compostos Organometálicos/uso terapêutico , Adolescente , Adulto , Antiprotozoários/administração & dosagem , Antiprotozoários/efeitos adversos , Criança , Terapia Combinada/efeitos adversos , Terapia Combinada/métodos , Crioterapia/efeitos adversos , Feminino , Seguimentos , Humanos , Injeções Intralesionais , Terapia a Laser/efeitos adversos , Lasers de Gás/efeitos adversos , Leishmaniose Cutânea/tratamento farmacológico , Leishmaniose Cutânea/cirurgia , Masculino , Meglumina/administração & dosagem , Meglumina/efeitos adversos , Antimoniato de Meglumina , Pessoa de Meia-Idade , Compostos Organometálicos/administração & dosagem , Compostos Organometálicos/efeitos adversos , Estudos Prospectivos , Fatores de Tempo , Resultado do Tratamento , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...